Literature DB >> 24063400

Metabolic profiling of biofluids: potential in lung cancer screening and diagnosis.

Iola F Duarte1, Cláudia M Rocha, Ana M Gil.   

Abstract

The knowledge that the organism's metabolome is a potentially informative mirror of the impact of disease and its dynamics has led to promising developments in cancer research, strongly geared toward the discovery of new biomarkers of disease onset and progression. The present text reviews the advances made in the last 10 years in lung cancer research making use of the metabolomics strategies, particularly concerning metabolite profiling of human biofluids (blood serum and plasma, urine and others), expected to reflect the deviant metabolic behavior of lung tumors. The main goal of this article is to provide the reader with an up-to-date summary of the main metabolic variations taking place in biofluids, in relation to lung cancer, as well as of the analytical strategies employed to unveil them. Furthermore, particular needs and challenges are identified and possible developments envisaged.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24063400     DOI: 10.1586/14737159.2013.835570

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  15 in total

1.  Cancer-Specific Production of N-Acetylaspartate via NAT8L Overexpression in Non-Small Cell Lung Cancer and Its Potential as a Circulating Biomarker.

Authors:  Tzu-Fang Lou; Deepa Sethuraman; Patrick Dospoy; Pallevi Srivastva; Hyun Seok Kim; Joongsoo Kim; Xiaotu Ma; Pei-Hsuan Chen; Kenneth E Huffman; Robin E Frink; Jill E Larsen; Cheryl Lewis; Sang-Won Um; Duk-Hwan Kim; Jung-Mo Ahn; Ralph J DeBerardinis; Michael A White; John D Minna; Hyuntae Yoo
Journal:  Cancer Prev Res (Phila)       Date:  2015-10-28

2.  Diagnosis of lung tumor types based on metabolomic profiles in lymph node aspirates.

Authors:  Daniel Sappington; Scott Helms; Eric Siegel; Rosalind B Penney; Susanne Jeffus; Teka Bartter; Thaddeus Bartter; Gunnar Boysen
Journal:  Cancer Treat Res Commun       Date:  2017-08-19

3.  The investigation of the volatile metabolites of lung cancer from the microenvironment of malignant pleural effusion.

Authors:  Ke-Cheng Chen; Shih-Wei Tsai; Xiang Zhang; Chian Zeng; Hsiao-Yu Yang
Journal:  Sci Rep       Date:  2021-06-30       Impact factor: 4.379

4.  Perioperative dynamics and significance of amino acid profiles in patients with cancer.

Authors:  Yu Gu; Tianxiang Chen; Suzhen Fu; Xin Sun; Lingyan Wang; Jian Wang; Yingfeng Lu; Songming Ding; Guodong Ruan; Lisong Teng; Min Wang
Journal:  J Transl Med       Date:  2015-01-27       Impact factor: 5.531

5.  Effects of pre-analytical processes on blood samples used in metabolomics studies.

Authors:  Peiyuan Yin; Rainer Lehmann; Guowang Xu
Journal:  Anal Bioanal Chem       Date:  2015-03-04       Impact factor: 4.142

6.  Radiation Changes the Metabolic Profiling of Melanoma Cell Line B16.

Authors:  Lige Wu; Zixi Hu; Yingying Huang; Yating Yu; Wei Liang; Qinghui Zheng; Xianing Huang; Yong Huang; Xiaoling Lu; Yongxiang Zhao
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

Review 7.  Noninvasive metabolic profiling for painless diagnosis of human diseases and disorders.

Authors:  Mainak Mal
Journal:  Future Sci OA       Date:  2016-06-10

Review 8.  Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: mini review.

Authors:  Li Yu; Kefeng Li; Xiaoye Zhang
Journal:  Oncotarget       Date:  2017-11-11

9.  The plasma glutamate concentration as a complementary tool to differentiate benign PET-positive lung lesions from lung cancer.

Authors:  K Vanhove; P Giesen; O E Owokotomo; L Mesotten; E Louis; Z Shkedy; M Thomeer; P Adriaensens
Journal:  BMC Cancer       Date:  2018-09-03       Impact factor: 4.430

10.  Circulating Tumor Cell and Metabolites as Novel Biomarkers for Early-Stage Lung Cancer Diagnosis.

Authors:  Lingling Wan; Qingyi Liu; Di Liang; Yongdong Guo; Guangjie Liu; Jinxia Ren; Yutong He; Baoen Shan
Journal:  Front Oncol       Date:  2021-05-31       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.